Literature DB >> 3038440

Antibody-independent activation of the classical pathway of complement by Epstein-Barr virus.

H Martin, I McConnell, B Gorick, N C Hughes-Jones.   

Abstract

A purified preparation of Epstein-Barr virus (EBV) has been shown to activate the classical complement pathway by direct interaction with the first component of complement, C1, without the intervention of antibody. No evidence was found for activation of the alternative pathway. Following classical pathway activation the specific affinity of EBV for B cells can be presumed to be lost since the virus will become opsonized for clearance by phagocytic cells bearing complement receptors, CR1 and CR3. This activation is further evidence that complement plays a role in defence mechanisms independently of antibody activity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3038440      PMCID: PMC1542632     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  18 in total

1.  Differences in activation of human and guinea pig complement by retroviruses.

Authors:  R M Bartholomew; A F Esser
Journal:  J Immunol       Date:  1978-11       Impact factor: 5.422

2.  The unactivated form of the first component of human complement, C1.

Authors:  I Gigli; R R Porter; R B Sim
Journal:  Biochem J       Date:  1976-09-01       Impact factor: 3.857

3.  Activation of the alternative complement pathway by human B cell lymphoma lines is associated with Epstein-Barr virus transformation of the cells.

Authors:  I McConnell; G Klein; T F Lint; P J Lachmann
Journal:  Eur J Immunol       Date:  1978-07       Impact factor: 5.532

4.  Receptors for the complement C3d component and the Epstein-Barr virus are quantitatively coexpressed on a series of B-cell lines and their derived somatic cell hybrids.

Authors:  V Jønsson; A Wells; G Klein
Journal:  Cell Immunol       Date:  1982-09-15       Impact factor: 4.868

5.  Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies.

Authors:  C B Laurell
Journal:  Anal Biochem       Date:  1966-04       Impact factor: 3.365

6.  Surface markers on human B and T lymphocytes. VIII. Association between complement and Epstein-Barr virus receptors on human lymphoid cells.

Authors:  M Jondal; G Klein; M B Oldstone; V Bokish; E Yefenof
Journal:  Scand J Immunol       Date:  1976       Impact factor: 3.487

7.  Interactions between mycoplasma pneumoniae and the first components of complement.

Authors:  W Bredt; B Wellek; H Brunner; M Loos
Journal:  Infect Immun       Date:  1977-01       Impact factor: 3.441

8.  Antibody-independent interaction of the first component of complement with Gram-negative bacteria.

Authors:  M Loos; B Wellek; R Thesen; W Opferkuch
Journal:  Infect Immun       Date:  1978-10       Impact factor: 3.441

9.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril.

Authors:  P J Fraker; J C Speck
Journal:  Biochem Biophys Res Commun       Date:  1978-02-28       Impact factor: 3.575

10.  Lysis of RNA tumor viruses by human serum: direct antibody-independent triggering of the classical complement pathway.

Authors:  N R Cooper; F C Jensen; R M Welsh; M B Oldstone
Journal:  J Exp Med       Date:  1976-10-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.